The antiepileptic drug phenytoin can cause cutaneous adverse reactions, ranging from maculopapular exanthema to severe cutaneous adverse reactions, which include drug reactions with eosinophilia and systemic symptoms, Stevens-Johnson syndrome, and toxic epidermal necrolysis. The pharmacogenomic basis of phenytoin-related severe cutaneous adverse reactions remains unknown.
adverse reactions include drug reactions with eosinophilia and systemic symptoms (DRESS), Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN). [4] [5] [6] Stevens-Johnson syndrome and TEN are variants of the same mucocutaneous blistering reaction disease and carry high morbidity and mortality (10%-50%). [4] [5] [6] DRESS, also known as drug-induced hypersensitivity syndrome, is characterized by generalized maculopapular eruptions, high fever, eosinophilia, atypical lymphocytes, and visceral involvement and has a mortality rate of approximately 10%. 6, 7 Phenytoinrelated severe cutaneous adverse reactions frequently impair the internal organs, leading to the highest mortality among the different antiepileptic drug-related cutaneous reactions. 5 The pharmacogenomic basis of phenytoin-related severe cutaneous adverse reactions remains unknown. By candidate gene approach, HLA-B*15:02 was identified as associated with phenytoin-related severe cutaneous adverse reactions in Asians; however, the strength of the association is much weaker than that found for carbamazepine-related SJS-TEN. [8] [9] [10] [11] [12] The US Food and Drug Administration has suggested that physicians should avoid prescribing phenytoin or fosphenytoin as an alternative to carbamazepine in patients who carry HLA-B*15:02. 13 To investigate the genetic factors associated with phenytoinrelated severe cutaneous adverse reactions, we carried out a genome-wide association study (GWAS) followed by direct sequencing of the associated genes and replication analyses using samples from Taiwan, Japan, and Malaysia.
Methods

Recruitment of Cases and Drug-Tolerant Controls
Patients with phenytoin-related cutaneous adverse reactions were recruited from the Chang Gung Memorial Hospital (CGMH) health system and Taiwan Severe Cutaneous Adverse Reactions Consortium in Taiwan, Hospital Sultanah Aminah Johor Bahru in Malaysia, and centers collaborating with the National Institute of Health Sciences and Osaka University in Japan between 2002 and 2014. All cases were evaluated by at least 2 dermatologists, who reviewed all available photographs, histological data, and clinical information, including type of cutaneous reactions, date of onset, and drug history, dosage, and duration. Phenotypes of severe cutaneous adverse reactions were clinically assessed using the diagnostic criteria established by the Registry of Severe Cutaneous Adverse Reactions Consortium, which maintains a multinational registry of severe cutaneous adverse reactions cases reported by physicians from many countries (Austria, France, Germany, Israel, Italy, the Netherlands, Spain, South Africa, Taiwan, the United Kingdom, and Vietnam, etc). 4, 7 Stevens-Johnson syndrome and TEN are characterized by a rapidly developing blistering exanthema of purpuric macules and target-like lesions accompanied by mucosal involvement and skin detachment. Stevens-Johnson syndrome was defined as skin detachment less than 10% of the body surface area, SJS-TEN overlap as skin detachment from 10% to 29%, and TEN as skin detachment greater than 30%. 4, 5 The criteria and scoring system of DRESS include cutaneous involvement with typical rash (eg, exfoliative dermatitis, diffuse maculopapular exanthema), fever, eosinophilia, lymph node enlargement, atypical lymphocytes, internal organ involvement (liver, kidney, central nervous system, lung, heart, muscle), and time of resolution. 7 The maculopapular exanthema phenotype is characterized by generalized cutaneous erythematous macules and papules and is self-limited without systemic involvement. We used 2 methods, the Naranjo score 14 and ALDEN (algorithm of drug causality for epidermal necrolysis), 15 to determine the drug causality as phenytoin. Drug-tolerant patients who had received phenytoin for more than 3 months without evidence of adverse reactions were enrolled as controls from the departments of neurology or neurosurgery of the CGMH health system in Taiwan in 2002-2014. Written informed consent was obtained from each participant. This study was approved by the institutional review board of the ethical standards committee of each study site/institute.
GWAS, Direct Sequencing, and Linkage Disequilibrium Analysis
GWAS was performed using the Affymetrix SNP Array 6.0 platform, which is composed of 909 622 single-nucleotide polymorphisms (SNPs). The genotype calls were generated using the Birdseed method (Birdseed version 2) with Affymetrix Power Tools (version apt- 
Analysis of Concentrations of Plasma Phenytoin
We obtained convenience plasma samples from phenytointolerant controls (including those with continuous use of phenytoin and those who were able to discontinue phenytoin therapy and provided their serial blood samples before or after drug withdrawal) and severe cutaneous adverse reactions cases. Plasma samples of controls who received the maintenance dosage were collected within 24 hours after the last dose of phenytoin. Available samples from phenytoin-tolerant controls and patients with severe cutaneous adverse reactions were obtained before or after withdrawal of phenytoin. The date of drug withdrawal in patients with severe cutaneous adverse reactions was usually the same day or near the onset of severe cutaneous adverse reactions when phenytoin was recognized as the associated drug. The plasma concentration of total phenytoin in samples was determined by fluorescence polarization immunoassay using Axsym Phenytoin Assay (Abbott) in the Department of Laboratory Medicine of the CGMH (College of American Pathologists number 3291201-02). Standard calibrators (0.0, 2.5, 5.0, 10.0, 20.0, and 40.0 μg/mL) were used to generate the standard curve. The assay system has a sensitivity of 0.5 μg/mL. This sensitivity is defined as the lowest measurable concentration that can be distinguished from zero with 95% confidence. Interday and intraday variability in precision were determined using human serum with 6.9, 14.0, and 24.0 μg/mL of phenytoin added, which yielded a coefficient of variation of less than 2.9%. Accuracy by recovery was determined by adding phenytoin to human serum and to buffer at concentrations of 2. 
Statistical Analysis
We conducted the statistical analysis for the association by comparing the allele or genotype frequencies between cases and controls in modes of inheritance (additive model, recessive model, or dominant models). The associations were examined by Fisher exact tests and rank-ordered according to the lowest P value in these models. All P values were 2-tailed. A Bonferroni correction was applied for the multiple comparisons and adjusted the P values using the numbers of tests (n=854 035 SNPs for GWAS, n=17 for HLA-A genotypes, and n=36 for HLA-B genotypes . The statistical significance was defined as P < .05. The concentrations of plasma phenytoin in the different groups were compared by nonparametric tests. Additional information regarding methods to determine drug causality, estimates of the prevalence of phenytoinrelated cutaneous adverse reactions, and HLA genotyping methods is provided in the eAppendix in the Supplement.
Results
For the initial GWAS, direct sequencing of the associated loci, and replication analysis, we enrolled a total of 168 cases with phenytoin-related cutaneous reactions (n=90 severe cutaneous adverse reactions [n=48 SJS-TEN and n=42 DRESS] and n=78 maculopapular exanthemas) and 130 tolerant controls from Taiwan ( Table 1) . Of the 90 cases with severe cutaneous adverse reactions, 13 patients died as a result of the episode (Table 1 ). The average daily dose of phenytoin showed no significant difference between the 90 severe cutaneous adverse reactions cases (mean, 314 mg/d; 95% CI, 292-330 mg/d) and 130 phenytoin-tolerant controls (mean, 323 mg/d; 95% CI, 309-337 mg/d; P=.42) ( Table 1 ). Based on the data from the Taiwan National Health Insurance and CGMH databases, the estimated prevalence was 0.24% for phenytoin-related SJS-TEN, 0.21% for phenytoin-related DRESS, and 3.6% for phenytoinrelated maculopapular exanthema in Taiwan.
As control participants in the GWAS, we randomly selected 412 healthy individuals from a Taiwan biobank under a nationwide population study, which comprises 9980 Han Chinese descendants. 16 There was no self-report of adverse drug events by any of these 412 participants from Taiwan, where 98% of the population is made up of Han Chinese. We performed the GWAS using samples from 60 cases of phenytoin-related severe cutaneous adverse reactions (n=38 SJS-TEN and n=22 DRESS) initially enrolled from a referral center (CGMH) and the 412 controls from Taiwan. The principal component analysis plots (eFigure 1 in the Supplement) could not separate the 60 severe cutaneous adverse reactions cases from 412 general controls, suggesting that there is no population stratification between cases and controls. The principal component analysis located most of the Taiwanese severe cutaneous adverse reactions cases as among southern, central, and northern Han Chinese of mainland China (eFigure 2 in the Supplement). The GWAS discovered a cluster of 16 SNPs on chromosome 10q23.33 (96.4-97.0 Mb) that reached the genome-wide significance threshold (P < 5.9 × 10 −8
) for association with phenytoinrelated severe cutaneous adverse reactions ( Figure 1 ). Eight SNPs with the lowest P values were located on CYP2C genes, comprising CYP2C18 (NCBI Entrez gene 1562), CYP2C19 (NCBI Entrez gene 1557), CYP2C9 (NCBI Entrez gene 1559), and CYP2C8 (NCBI Entrez gene 1558) ( Table 2 ). The quantile-quantile plot confirmed a marked excess of significantly associated SNPs on chromosome 10 (eFigure 3 in the Supplement). Direct sequencing of the CYP2C genes of patients identified 2 missense variants, rs1057910 (CYP2C9*3; p.I359L) and rs3758581 (CYP2C19*1C; p.V331I), showing statistically significant association with phenytoin-related severe cutaneous adverse reactions (Table 2 and eTable 2 in the Supplement). The association between the 10 variants and phenytoin-related severe cutaneous adverse reactions was replicated in an independent set of 30 cases of phenytoin-related severe cutaneous adverse reaction (n=10 SJS-TEN and n=20 DRESS) recruited from the Taiwan Severe Cutaneous Adverse Reactions Consortium and 130 phenytointolerant controls (Table 2 ). All 10 SNPs in the 412 general controls were in Hardy-Weinberg equilibrium ( Table 2) .
The 10 SNPs are common (minor allele frequencies ≥0.19) in severe cutaneous adverse reactions cases, yet rare (minor allele frequencies 0.017-0.063) in the population controls from Taiwan (n = 412) and the southern (n = 500), central (n = 500), and northern (n = 500) Han Chinese samples (eTable 3 in the Supplement). The 10 SNPs showed strong linkage disequilibrium in the data sets of 412 controls and 90 severe cutaneous adverse reactions cases but a smaller linkage disequilibrium block in 130 phenytoin-tolerant controls ( Figure 2 and eTables 4-6 and eFigure 4 in the Supplement). Among the 7 haplotypes inferred from 3 SNPs (rs3758581, rs1057910, and rs6583967), the risk haplotype (haplotype 2) was absent in 130 phenytoin-tolerant controls and showed significant association with phenytoin-related severe cutaneous adverse reactions (eFigure 5 in the Supplement). Because the estimated prevalence of phenytoin-related severe cutaneous adverse reactions is very low in Taiwan, the genotyping data of 130 phenytoin-tolerant controls and 412 population controls was combined. All 10 SNPs exhibited significant association with phenytoin-related severe cutaneous adverse reactions in the combined-samples analysis (90 cases and 542 controls) and showed P>.05 for heterogeneity between studies (Table 2) . Data from the GWAS, replication, and combined-samples analysis all revealed that CYP2C9*3 showed significant association with 56 (17) 63 (3.5) 64 (16) 57 (21) 57 (17) 52 (21) 41 (14) Median ( b Values of glutamic-pyruvic transaminase were 2 times greater than normal.
c The creatinine value was 1.5-fold higher than the normal value range (0.4-1.5 mg/dL) after drug intake.
sis) ( Table 2) . We compared the SNP data of the subgroups of 168 patients with phenytoin-related cutaneous adverse reactions and 130 phenytoin-tolerant controls and found that CYP2C9*3 exhibited significant association with phenytoin-related SJS-TEN (OR, 30; 95% CI, 8.4-109; P = 1.2×10 −10 ), DRESS (OR, 19; 95% CI, 5.1-71; P = 7.0×10 −7 ), and maculopapular exanthema (OR, 5.5; 95% CI, 1.5-21; P = .01) (eTable 7 in the Supplement). The significant association between CYP2C9*3 and phenytoinrelated cutaneous adverse reactions was also noted when comparing data from cases with that of the 412 population controls (eTable 7). We examined the association between CYP2C9*3 and phenytoin-related severe cutaneous adverse reactions using graphic and clinical data for patients with phenytoin-related severe cutaneous adverse reactions from Japan and Malaysia are shown in eTable 8 in the Supplement. Allele frequencies of CYP2C9*3 were 17% to 22% in samples from patients with phenytoin-related severe cutaneous adverse reactions but only 2.7% to 2.8% in samples from the population controls of Japan and Malaysia (eTable 9 in the Supplement). CYP2C9*3 showed statistically significant association with phenytoinrelated severe cutaneous adverse reactions in both Japanese (OR, 10; 95% CI, 3.4-32; P = 1.2 × 10 −3
) and Malaysians (OR, 6.9; 95% CI, 1.4-34; P = .048) (eTable 9). We further analyzed the association between CYP2C9*3 and phenytoin-related severe cutaneous adverse reactions by meta-analysis using a randomeffects model and classified cases and controls according to their phenotype (SJS-TEN or DRESS) and ethnicity (Taiwanese, Japanese, or Malaysian) (Figure 3) . The results of the metaanalysis showed a pooled OR of 12 (95% CI, 6.4-22; z = 7.82; P < .00001) for a CYP2C9*3 association with phenytoinrelated SJS-TEN, a pooled OR of 9.2 (95% CI, 4.3-20; z = 5.70; P < .00001) for a CYP2C9*3 association with phenytoinrelated DRESS, and an overall OR of 11 (95% CI, 6.2-18; z = 8.58; P < .00001) for a CYP2C9*3 association with phenytoinrelated severe cutaneous adverse reactions in Asians (Figure 3 ).
Although no SNPs on HLA region reached genome-wide significance, we examined the HLA association because of the immunological characteristics of phenytoin-related severe cutaneous adverse reactions. [3] [4] [5] [6] 18 ; P = .025 after Bonferroni correction) (eTable 10). Adding HLA-B*1502 to CYP2C9*3 genetic screening improved the sensitivity to 62.5% for phenytoin-related SJS-TEN but decreased the specificity (eTable 11 in the Supplement).
The concentrations of plasma phenytoin were determined in the samples of participants, including (1) 90 phenytointolerant controls with continuous use of phenytoin; (2) 11 phenytoin-tolerant controls who were able to discontinue phenytoin therapy; (3) 14 patients with SJS-TEN; and (4) 26 patients with DRESS (Table 3 and eFigure 6 in the Supplement). The average concentration of plasma phenytoin in the 90 phenytointolerant controls was 11.8 μg/mL (95% CI, 11.0-12.6 μg/mL) ( Table 3 ). The day of drug withdrawal in the 11 phenytointolerant controls and 40 patients with severe cutaneous adverse reactions was labeled as day 0 (eFigure 6, B-D). Nine samples from patients with severe cutaneous adverse reac- e P values were calculated by Fisher exact test for the risk allele. All SNPs were discovered by the GWAS except rs3758581 and rs1057910, which were identified by direct sequencing on the associated genes.
tions were obtained before drug withdrawal because these patients were hospitalized and received phenytoin for seizure prophylaxis. Before drug withdrawal, plasma concentrations of phenytoin were significantly higher in patients with SJS-TEN (mean, 34 μg/mL; 95% CI, 1.8-66 μg/mL) compared with the phenytoin-tolerant controls (mean, 11 μg/mL; 95% CI, 9.1-13 μg/ mL; P = .015) ( Table 3) . After drug withdrawal for 1 to 5 days, concentrations of plasma phenytoin rapidly decreased in phenytointolerant controls (mean, 2.5 μg/mL; 95% CI, 1.5-3.5 μg/mL) but remained significantly high in patients with SJS-TEN (mean, 12 μg/mL; 95% CI, 4.6-19 μg/mL; P = .0004) and patients with DRESS (mean, 5.5 μg/mL; 95% CI, 2.8-8.3 μg/mL; P = .029) ( Table 3) . Furthermore, significantly delayed clearance of plasma phenytoin was observed in patients with severe cutaneous adverse reactions with CYP2C9*3 (mean, 17 μg/mL; 95% CI, 5.9-27 μg/mL; P = .0002) and in noncarriers (mean, 4.9 μg/mL; 95% CI, 3.1-6.7 μg/mL; P = .015) ( Table 3 ). The CYP2C9*3 carriers with severe cutaneous adverse reactions had significantly higher levels of plasma phenytoin than patients without the risk allele (P = .022). However, the average daily dose showed no difference between patients with severe cutaneous adverse reactions carrying CYP2C9*3 (n = 12; mean, 300 mg/d; 95% CI, 300-300 mg/d) and noncarriers (n = 28; mean, 304 mg/d; 95% CI, 291-316 mg/ d). These data suggest that rs1057910 (CYP2C9*3) contributes to phenytoin-related severe cutaneous adverse reactions.
Discussion
Phenytoin has a narrow therapeutic range (10-20 μg/mL) and nonlinear pharmacokinetics and is metabolized to inactive hydroxyphenytoin, 5-(4'-hydroxyphenyl)-5-phenylhydantoin (p-HPPH), primarily (90%) by the cytochrome P450 (CYP) 2C9 enzyme. 19 Formation of p-HPPH is thought to proceed via a reactive arene oxide intermediate, which has been proposed for the induction of phenytoin hypersensitivity. 19, 20 In this study, we report CYP2C variants, including CYP2C9*3, known to cause 93% to 95% reduction in phenytoin clearance, [21] [22] [23] [24] as important genetic factors for phenytoin-related severe cutaneous adverse reactions. We detected accumulated phenytoin in patients with severe cutaneous adverse reactions, particularly CYP2C9*3 carriers. Patients with SJS-TEN exhibited slower metabolism and a stronger strength of association with the CYP2C SNPs than patients with DRESS. Delayed clearance was also noted in patients with severe cutaneous adverse reactions without CYP2C9*3, suggesting that nongenetic factors such as renal insufficiency, hepatic dysfunction, and concurrent use of substances that compete or inhibit the enzymes may also affect phenytoin metabolism and contribute to severe cutaneous adverse reactions. Such characteristics share the features of the drug-accumulation hypothesis of allopurinol-related severe cutaneous adverse reactions, in which the risk factors include highdose regimen, renal failure, concomitant diuretic, and high concentration of oxypurinol. [25] [26] [27] Further studies are needed to investigate how the CYP2C variants and the accumulated reactive metabolites affect cutaneous adverse reactions. Among the 10 risk alleles, the missense rs1057910 is the only one with known function associated with reduced CYP2C9 enzyme activity and phenytoin-related neurological toxicity. 22, 23 The SNP rs1057910 forms CYP2C9*3 and part of CYP2C9*18. Another risk SNP, rs3758581, present on the CYP2C19*1B and CYP2C19*1C normal haplotypes, is a missense mutation yet has no obvious effects on CYP2C19 activity or drug metabolism. 24, 28, 29 The SNP rs3758581 may be a surrogate marker for rs1057910 because of the strong linkage disequilibrium between the 2 SNPs. In our 90 samples from patients with severe cutaneous adverse reactions, we did not detect CYP2C9*2 (rs1799853). The frequencies of CYP2C9*3 vary in ethnic groups (0.8%-10%). 28-30 CYP2C9*3 was reported to be associated with phenytoin maculopapular exanthema (P = .007) in Koreans. 31 A GWAS using samples from 40 cases wide significant variants; this may be explained by the limited sample size and maculopapular exanthema phenotype of most of the cases.
This study has several limitations. The sample sizes of severe cutaneous adverse reaction cases and phenytointolerant controls were small, and we did not have samples from other population groups to replicate the genetic association. For the pharmacokinetic analysis, we had only a few available plasma samples, and most of the severe cutaneous adverse reaction samples were collected after drug withdrawal. Additionally, drug-tolerant participants were younger and more likely to be male than patients with severe cutaneous adverse reactions, which may account for some of the observed differences in drug metabolism.
This study highlights that genetic variants of metabolizing enzymes contribute to severe cutaneous adverse reactions, which is different from the previous HLA studies. [33] [34] [35] [36] [37] [38] Although the clinical manifestations and prognosis are quite different between SJS-TEN and DRESS, our data suggest some shared genetic factors. We propose that delayed clearance and accumulation of reactive metabolites caused by genetic variants of drug-metabolizing enzymes may be the primary factor, and that immunogenicity, such as the presence of risk HLA alleles and specific T-cell receptor clonotypes in susceptible individuals, may facilitate the development and guide the different types of cutaneous adverse reactions. 39, 40 Further investigation is required to determine how a complex interplay of impaired drug metabolism, accumulation of reactive drug compounds, HLA presentation of the drug/peptide antigens, T-cell receptor recognition, and historical immune memory triggers drug hypersensitivity.
Conclusions
This study identified CYP2C variants, including CYP2C9*3, known to reduce drug clearance, as important genetic factors associated with phenytoin-related severe cutaneous adverse reactions. These findings may have potential to improve the safety profile of phenytoin in clinical practice and offer the possibility of prospective testing for preventing phenytoinrelated severe cutaneous adverse reactions. More research is required to replicate the genetic association in different populations and to determine the test characteristics and clinical utility. Abbreviations: DRESS, drug reaction with eosinophilia and systemic symptoms; SJS, Stevens-Johnson syndrome; TEN, toxic epidermal necrolysis. a The plasma samples for the pharmacokinetic analysis were based on sample availability; more than 1 sample could be obtained from a particular participant at different time points. b P values were calculated by nonparametric tests for the comparison between the difference of plasma phenytoin concentrations in the cases and 11 phenytoin-tolerant controls. c A nonparametric test was used to examine the differences in the time interval after drug withdrawal among the samples obtained from the subgroups. No significant difference in time intervals was found between the subgroups of cases and 11 phenytoin-tolerant controls.
